Allospecific CD8+ Tc1 and Tc2 Populations in Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease

Journal of Immunology

Volumn 157, Issue 11, 1996, Pages 4811-4821

  Fowler, Daniel H ^a,c   Breglio, Jeffrey ^a   Nagel, Gregg ^a   Eckhaus, Michael A ^b   Gress, Ronald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYTOKINE; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; LIGAND; MEMBRANE PROTEIN;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; C3H MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CLASSIFICATION; CYTOTOXICITY; DRUG EFFECT; EXPERIMENTAL LEUKEMIA; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; IN VITRO STUDY; INTESTINE; LIVER; MOUSE; PATHOLOGY; SECRETION; T LYMPHOCYTE SUBPOPULATION;

ACETYLCYSTEINE; ANIMALS; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HUMANS; INTESTINES; LEUKEMIA, EXPERIMENTAL; LIGANDS; LIVER; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030472309     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Champlin, R. 1995. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol. 23:1148.
2. Truitt, R. L., and B. D. Johnson. 1995. Principles of graft-vs.-leukemia reactivity. Biol. Blood Marrow Transplant. 1:61.
3. Quinones, R. R., R. H. Gutierrez, P. A. Dinndorf, R. E. Gress, A. B. Ney, B. Taylor, S. Karandish, C. S. Carter, N. L. Luban, and G. H. Reaman. 1993. Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. Blood 82:307.
4. Johnson, B. D., W. R. Drobyski, and R. L. Truitt. 1993. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant. 11:329.
5. Kolb, H. J., A. Schattenberg, J. M. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, and D. Niederwieser. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041.
6. Giralt, S., J. Hester, Y. Huh, C. Hirsch-Ginsberg, G. Rondon, D. Seong, M. Lee, J. Gajewski, K. Van Besien, and I. Khouri. 1995. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337.
7. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348.
8. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279.
9. Croft, M., L. Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715.
10. + T cells secreting Th1 or Th2 cytokines. Immunity 2:271.
11. Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzofsky, T. R. Mosmann, S. L. James, H. C. Morse, and G. M. Shearer. 1992. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol. Rev. 127:183.
12. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179:589.
13. Romagnani, S. 1994. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12:227.
14. Clerici, M., and G. M. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15:575.
15. + lymphoid engraftment. J. Immunol. 152:1004.
16. Fowler, D. H., K. Kurasawa, R. Smith, M. A. Eckhaus, and R. E. Gress. 1994. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540.
17. Carter, L. L., and R. W. Dutton. 1995. Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations. J. Immunol. 155:1028.
18. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant. 8:51.
19. + cells in class I different hosts. J. Exp. Med. 167:556.
20. + donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol. 155:585.
21. Carlesso, N., J. D. Griffin, and B. J. Druker. 1994. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9:149.
22. + subset of mature T lymphocytes. J. Immunol. 138:1.
23. Wunderlich, J., and G. Shearer. 1992. Induction and measurement of cytotoxic T lymphocyte activity. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Marguilies, E. M. Shevach, and W. Strober, eds. John Wiley and Sons, New York, p. 3.11.4.
24. +-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195.
25. Marshak-Rothstein, A., P. Fink, T. Gridley, D. H. Raulet, M. J. Bevan, and M. L. Gefter. 1979. Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus. J. Immunol. 122:2491.
26. - cells that make TH2 cytokines and help B cells. Science 260:1802.
27. Hockenbery, D. M., Z. N. Oltvai, X. M. Yin, C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241.
28. Kurita, T., and H. Namiki. 1994. Apoptotic cell death induced by serum and its prevention by thiols. J. Cell. Physiol. 161:63.
29. Williams, M., and P. A. Henkart. 1996. Role of reactive oxygen intermediates in TCR-induced death of T cell blasts and hybridomas. J. Immunol. 157:2395.
30. Kantarjian, H. M., A. Deisseroth, R. Kurzrock, Z. Estrov, and M. Talpaz. 1993. Chronic myelogenous leukemia: a concise update. Blood 82:691.
31. Matulonis, U. A., C. Dosiou, C. Lamont, G. J. Freeman, P. Mauch, L. M. Nadler, and J. D. Griffin. 1995. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507.
32. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
33. Antin, J. H., and J. L. Ferrara. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964.
34. Lynch, D. H., and R. E. Miller. 1994. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J. Exp. Med. 179:31.
35. Kos, F. J., and A. Mullbacher. 1992. Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7. Eur. J. Immunol. 22:3183.
36. Grabstein, K. H., A. E. Namen, K. Shanebeck, R. F. Voice, S. G. Reed, and M. B. Widmer. 1990. Regulation of T cell proliferation by IL-7. J. Immunol. 144:3015.
37. Rich, B. E., J. Campos-Torres, R. I. Tepper, R. W. Moreadith, and P. Leder. 1993. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J. Exp. Med. 177:305.
38. Grabstein, K. H., T. J. Waldschmidt, F. D. Finkelman, B. W. Hess, A. R. Alpert, N. E. Boiani, A. E. Namen, and P. J. Morrissey. 1993. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J. Exp. Med. 178:257.
39. Bhatia, S. K., L. T. Tygrett, K. H. Grabstein, and T. J. Waldschmidt. 1995. The effect of in vivo IL-7 deprivation on T cell maturation. J. Exp. Med. 181:1399.
40. Sato, N., S. Iwata, K. Nakamura, T. Hori, K. Mori, and J. Yodoi. 1995. Thiol-mediated redox regulation of apoptosis: possible roles of cellular thiols other than glutathione in T cell apoptosis. J. Immunol. 154:3194.
41. Yim, C. Y., J. B. Hibbs, Jr., J. R. McGregor, R. E. Galinsky, and W. E. Samlowski. 1994. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J. Immunol. 152:5796.
42. Kroemer, G., and C.-A. Martinez. 1994. Pharmacological inhibition of programmed lymphocyte death. Immunol. Today 15:235.
43. Henkart, P. A. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343.
44. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
45. Ramsdell, F., M. S. Seaman, R. E. Miller, T. W. Tough, M. R. Alderson, and D. H. Lynch. 1994. gld/gld mice are unable to express a functional ligarid for Fas. Eur. J. Immunol. 24:928.
46. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I. A. Roberts, K. M. Debatin, A. Fischer, and J. P. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347.
47. Galle, P. R., W. J. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P. H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223.
48. Braun, M. Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657.
49. Baker, M., and R. B. Levy. 1996. Distinct roles of perforin and Fas-dependent donor antihost cytotoxicity in acute GVHD. In Graft-vs-Host Disease, 2nd Ed. J. L. M. Ferrara, H. J. Deeg, and S. J. Burakoff, eds. Marcel Dekker, New York, pp. 786-790.
50. Rensing-Ehl, A., K. Frei, R. Flury, B. Matiba, S. M. Mariani, M. Weller, P. Aebischer, P. H. Krammer, and A. Fontana. 1995. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25:2253.